Literature DB >> 22977567

Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity.

Sílvia Busquets1, Míriam Toledo, Sònia Sirisi, Marcel Orpí, Roberto Serpe, Joana Coutinho, Raquel Martínez, Josep M Argilés, Francisco J López-Soriano.   

Abstract

Cancer cachexia occurs in the majority of cancer patients before death, and it is responsible for the death of 22% of cancer patients. One of the most relevant characteristics of cachexia is that of asthenia, which reflects significant muscle wasting noted in cachectic cancer patients The aim of the present study was to assess whether the β(2)-adrenergic agonist formoterol is associated with an improvement in physiological parameters such as grip force and total physical activity in cachetic rats. Administration of the β(2)-agonist formoterol (0.3 mg/kg for 7 days) in rats bearing Yoshida AH-130 ascites hepatoma tumors, a model which induces a strong loss of both body and muscle weight, resulted in a significant reversal of the muscle wasting process, as reflected by individual muscle weights. The anti-wasting effects of the drug were also observed in terms of total physical activity and grip force, thus resulting in an improvement in physical performance in cachectic tumor-bearing rats.

Entities:  

Year:  2011        PMID: 22977567      PMCID: PMC3440697          DOI: 10.3892/etm.2011.260

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

Review 1.  The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease.

Authors:  Donald A Mahler
Journal:  J Allergy Clin Immunol       Date:  2002-12       Impact factor: 10.793

Review 2.  Management of cancer cachexia.

Authors:  W DeWys
Journal:  Semin Oncol       Date:  1985-12       Impact factor: 4.929

3.  Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondria-mediated pathway.

Authors:  Aude Zangarelli; Emilie Chanseaume; Béatrice Morio; Corinne Brugère; Laurent Mosoni; Paulette Rousset; Christophe Giraudet; Véronique Patrac; Pierre Gachon; Yves Boirie; Stéphane Walrand
Journal:  FASEB J       Date:  2006-12       Impact factor: 5.191

4.  Cancer cachexia: physical activity and muscle force in tumour-bearing rats.

Authors:  Míriam Toledo; Sílvia Busquets; Sònia Sirisi; Roberto Serpe; Marcel Orpí; Joana Coutinho; Raquel Martínez; Francisco J López-Soriano; Josep M Argilés
Journal:  Oncol Rep       Date:  2011-01       Impact factor: 3.906

Review 5.  Cytokines as mediators and targets for cancer cachexia.

Authors:  Josep M Argilés; Sílvia Busquets; Francisco J López-Soriano
Journal:  Cancer Treat Res       Date:  2006

6.  Nutritional assessment and patient outcome during oncological therapy.

Authors:  K B Harvey; A Bothe; G L Blackburn
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

7.  Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.

Authors:  Sílvia Busquets; Maria T Figueras; Gemma Fuster; Vanessa Almendro; Rodrigo Moore-Carrasco; Elisabet Ametller; Josep M Argilés; Francisco J López-Soriano
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice.

Authors:  M Llovera; C García-Martínez; J López-Soriano; N Carbó; N Agell; F J López-Soriano; J M Argiles
Journal:  Mol Cell Endocrinol       Date:  1998-07-25       Impact factor: 4.102

9.  Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.

Authors:  Gemma Fuster; Sílvia Busquets; Elisabet Ametller; Mireia Olivan; Vanessa Almendro; Cibely Cristine Fontes de Oliveira; Maite Figueras; Francisco J López-Soriano; Josep M Argilés
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance.

Authors:  C Lanigan; T Q Howes; G Borzone; L G Vianna; J Moxham
Journal:  Eur Respir J       Date:  1993-09       Impact factor: 16.671

View more
  4 in total

1.  Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats.

Authors:  Anna Salazar-Degracia; Sílvia Busquets; Josep M Argilés; Francisco J López-Soriano; Esther Barreiro
Journal:  PeerJ       Date:  2017-12-13       Impact factor: 2.984

Review 2.  Cancer-induced muscle wasting: latest findings in prevention and treatment.

Authors:  Zaira Aversa; Paola Costelli; Maurizio Muscaritoli
Journal:  Ther Adv Med Oncol       Date:  2017-03-08       Impact factor: 8.168

3.  Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model.

Authors:  Silvia Busquets; Marta Castillejo; Queralt Jové; Baptiste Jude; Patricia Mejías; Francisco J López-Soriano; Josep M Argilés
Journal:  Onco Targets Ther       Date:  2021-03-17       Impact factor: 4.147

4.  A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.

Authors:  Míriam Toledo; Fabio Penna; Francesc Oliva; Melania Luque; Angelica Betancourt; Enrica Marmonti; Francisco J López-Soriano; Josep M Argilés; Sílvia Busquets
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-05-14       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.